← All trials
NCT04918667
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 30, 2021
- Primary completion
- Nov 30, 2021
- Completion date
- Dec 31, 2022
- First posted
- Jun 9, 2021
- Last posted
- Aug 18, 2021
- Enrollment
- 16
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- EuroPharma, Inc.Lead sponsor
- Government of ArmeniaOverall official - principal investigator
- Government of ArmeniaCollaborator
- Government of ArmeniaOverall official - principal investigator
- Government of ArmeniaCollaborator
- Institute of Fine Organic Chemistry of the National Academy of Science, ArmeniaOverall official - principal investigator
- Institute of Fine Organic Chemistry of the National Academy of Science, ArmeniaCollaborator
- Phytomed ABStudy director
- Phytomed ABCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.